Cargando…
Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence
We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc stu...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773364/ https://www.ncbi.nlm.nih.gov/pubmed/35052816 http://dx.doi.org/10.3390/biomedicines10010137 |
_version_ | 1784636066479734784 |
---|---|
author | Peeters, Laura E. J. Tjong, Leonardien K. Rietdijk, Wim J. R. van Gelder, Teun Koch, Birgit C. P. Versmissen, Jorie |
author_facet | Peeters, Laura E. J. Tjong, Leonardien K. Rietdijk, Wim J. R. van Gelder, Teun Koch, Birgit C. P. Versmissen, Jorie |
author_sort | Peeters, Laura E. J. |
collection | PubMed |
description | We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc study had all participated in a single-blind randomized controlled trial called RHYME-RCT (Dutch Trial Register, NL6736). Concentrations in blood of several AHDs were assessed in RHYME-RCT to investigate adherence to treatment. This allowed for a comparison of drug exposure to spironolactone and canrenone between males and females. In linear regression models, no statistically significant sex differences (N = 35) in spironolactone (B =−10.23, SE = 7.92, p = 0.206) or canrenone (B = 1.24, SE = 10.96, p = 0.911) concentrations after adjustment for dose and time between sampling and intake were found. Furthermore, no statistically significant differences in non-adherence to spironolactone were found between sexes (N = 54, male 15% vs. female 38%, p = 0.100), but non-adherence to spironolactone was associated with non-adherence to other AHDs (p ≤ 0.001). Spironolactone and canrenone concentrations were not different between males and females with resistant hypertension. Although not statistically significant, females were twice as likely to be non-adherent to spironolactone compared to males, and thereby also more likely to be non-adherent to other AHDs. |
format | Online Article Text |
id | pubmed-8773364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87733642022-01-21 Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence Peeters, Laura E. J. Tjong, Leonardien K. Rietdijk, Wim J. R. van Gelder, Teun Koch, Birgit C. P. Versmissen, Jorie Biomedicines Article We aim to investigate sex differences in blood concentrations of spironolactone and the active metabolite canrenone in resistant hypertension patients. Furthermore, sex differences in adherence for spironolactone and other antihypertensive drugs (AHDs) were studied. The patients in this post hoc study had all participated in a single-blind randomized controlled trial called RHYME-RCT (Dutch Trial Register, NL6736). Concentrations in blood of several AHDs were assessed in RHYME-RCT to investigate adherence to treatment. This allowed for a comparison of drug exposure to spironolactone and canrenone between males and females. In linear regression models, no statistically significant sex differences (N = 35) in spironolactone (B =−10.23, SE = 7.92, p = 0.206) or canrenone (B = 1.24, SE = 10.96, p = 0.911) concentrations after adjustment for dose and time between sampling and intake were found. Furthermore, no statistically significant differences in non-adherence to spironolactone were found between sexes (N = 54, male 15% vs. female 38%, p = 0.100), but non-adherence to spironolactone was associated with non-adherence to other AHDs (p ≤ 0.001). Spironolactone and canrenone concentrations were not different between males and females with resistant hypertension. Although not statistically significant, females were twice as likely to be non-adherent to spironolactone compared to males, and thereby also more likely to be non-adherent to other AHDs. MDPI 2022-01-08 /pmc/articles/PMC8773364/ /pubmed/35052816 http://dx.doi.org/10.3390/biomedicines10010137 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Peeters, Laura E. J. Tjong, Leonardien K. Rietdijk, Wim J. R. van Gelder, Teun Koch, Birgit C. P. Versmissen, Jorie Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title | Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title_full | Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title_fullStr | Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title_full_unstemmed | Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title_short | Sex Differences in Spironolactone and the Active Metabolite Canrenone Concentrations and Adherence |
title_sort | sex differences in spironolactone and the active metabolite canrenone concentrations and adherence |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773364/ https://www.ncbi.nlm.nih.gov/pubmed/35052816 http://dx.doi.org/10.3390/biomedicines10010137 |
work_keys_str_mv | AT peeterslauraej sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence AT tjongleonardienk sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence AT rietdijkwimjr sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence AT vangelderteun sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence AT kochbirgitcp sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence AT versmissenjorie sexdifferencesinspironolactoneandtheactivemetabolitecanrenoneconcentrationsandadherence |